Embecta cut its quarterly dividend from 15 cents a share to one cent, and its stock lost 57.8% in a single day. That was May 5, 2026, the day the diabetes-care company reported second-quarter fiscal 2026 results. Shareholders have since filed securities fraud class actions, and several law firms have announced them.
The suits cover statements Embecta made between November 25, 2025 and May 4, 2026. During that stretch, management repeatedly called its core pen needle business resilient and resolute. Plaintiffs say those assurances hid softening market volume and the loss of a major customer, and that neither came to light until the second-quarter report.
May 5
The report showed a sharp revenue decline. Embecta also cut its full-year adjusted earnings-per-share guidance by 43%. Along with the dividend reduction, the market response was immediate.
Reed Kathrein, a partner at Hagens Berman, said his firm is examining whether the earlier executive assurances amount to actionable securities violations. Investors who held shares during the class period have until August 17, 2026 to seek appointment as lead plaintiff.
Notices from other firms followed through the summer. Bernstein Liebhard LLP said on June 25 that a shareholder had filed a class action. Bleichmar Fonti & Auld LLP and Robbins LLP announced the case in July, and Kaplan Fox & Kilsheimer LLP sent several of its own, including one on August 12. The allegations have not been tested in court.
The company behind the needles
Embecta, based in Parsippany, New Jersey, makes pen needles, syringes and safety injection devices for people living with diabetes, and sells mostly through wholesalers and distributors. It reported fiscal 2025 revenue of $1.08 billion, down 3.8% from $1.12 billion.
The company has been trying to widen its range, with the Owen Mumford acquisition and new partnerships. On August 7 it reported third-quarter revenue of $271.7 million against a consensus of $254.54 million, and said revenue rose by roughly $50 million from the previous quarter. It declared another quarterly dividend of one cent per share.
Analysts remain cautious. BofA’s Travis Steed lowered his price target to $3 from $11 and kept an Underperform rating. Among four analysts, the average rating is Hold, with a 12-month target of $4.
Sources
- Embecta Faces Shareholder Lawsuit Over Insulin Pen Needle Sales
- Embecta (EMBC) Stock Price, Chart & News
